|
Sanchez-Montalva A, Caminero JA, Guna MR, Sanz TR, Rabunal R, Millet JP, Gullon-Blanco JA, Anibarro L, Perez-Mendoza G, Medina JF, Gonzalez-Galan V, Tabernero E; Writing committee of the Spanish MDR TB consortium (in alphabetical order); Annex. Members of the Spanish MDR TB consortium group. Executive summary: Clinical practice guidelines on the management of resistant tuberculosis of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Enferm Infecc Microbiol Clin (Engl Ed). 2024 Dec;42(10):588-596. doi: 10.1016/j.eimce.2024.09.001. PubMed PMID: 39626979.
AÑO: 2024
|
39626979
|
Pons-Fuster E, Bernal E, Guillamon CF, Gimeno L, Martinez-Sanchez MV, Ruiz-Lorente I, Campillo JA, Ceballos D, Torres A, Tomas C, Munoz A, Alcaraz A, Selma P, Ruiz-Nicolas C, Muro M, Minguela A. HLA-C*07 is associated with symptomatic HIV-1-associated neurocognitive disorders (HAND) and immune dysregulation. Infect Dis (Lond). 2024 Oct;56(10):818-829. doi: 10.1080/23744235.2024.2351047. Epub 2024 May 14. PubMed PMID: 38743055.
AÑO: 2024; IF: 2.3
|
|
Ruzafa Martinez C, Valero S, Garcia Villalba E, Tomas C, Munoz A, Alcaraz A, Martinez-Rodriguez R, Hernandez MD, Martinez MI, Vicente MR, Guijarro Westermeyer E, Gonzalez Hipolito R, Bernal E. Vaccine effectiveness in patients admitted for influenza during the 2023-2024 season. Med Clin (Barc). 2024 Dec 27;163(12):589-594. doi: 10.1016/j.medcli.2024.07.023. Epub 2024 Oct 15. English, Spanish. PubMed PMID: 39414550.
AÑO: 2024; IF: 2.1
|
|
Bernal E, Garcia-Villalba E, Pons E, Hernandez MD, Baguena C, Puche G, Carter P, Martinez M, Alcaraz A, Tomas C, Munoz A, Vicente MR, Nunez ML, Sancho N, Villalba MC, Cano A, Minguela A. Remdesivir plus dexamethasone is associated to improvement in the clinical outcome of COVID-19 hospitalized patients regardless of their vaccination status. Med Clin (Barc). 2023 Aug 25;161(4):139-146. doi: 10.1016/j.medcli.2023.03.025. Epub 2023 Apr 5. PubMed PMID: 37100681; PubMed Central PMCID: PMC10073576.
AÑO: 2023; IF: 2.6
|
|
Santos JR, Domingo P, Portilla J, Gutierrez F, Imaz A, Vilchez H, Curran A, Valcarce-Pardeiro N, Payeras A, Bernal E, Montero-Alonso M, Yzusqui M, Clotet B, Videla S, Molto J, Paredes R. A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes. Open Forum Infect Dis. 2023 Oct 31;10(11):ofad542. doi: 10.1093/ofid/ofad542. eCollection 2023 Nov. PubMed PMID: 38023553; PubMed Central PMCID: PMC10661076.
AÑO: 2023; IF: 3.8
|